---
title: "INBX.US (INBX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/INBX.US/news.md"
symbol: "INBX.US"
name: "INBX.US"
parent: "https://longbridge.com/en/quote/INBX.US.md"
datetime: "2026-05-21T22:33:05.683Z"
locales:
  - [en](https://longbridge.com/en/quote/INBX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/INBX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/INBX.US/news.md)
---

# INBX.US (INBX.US) — Related News

### [TRANSCENTA-B's partner INHIBRX reports the latest positive data on OZEKIBART's CRC and announces the submission of a BLA application to the U.S. for the treatment of soft tissue sarcoma](https://longbridge.com/en/news/287126678.md)
*2026-05-20T22:27:03.000Z*
> TRANSCENTA-B announced that its partner Inhibrx reported positive mid-term data for ozekibart in combination with FOLFIR

### [Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)](https://longbridge.com/en/news/286568281.md)
*2026-05-15T12:45:25.000Z*
> Stifel Nicolaus has maintained a Buy rating for Inhibrx Biosciences Inc (INBX) with a price target of $325.00. Analyst D

### [Inhibrx Reports First Quarter 2026 Financial Results | INBX Stock News](https://longbridge.com/en/news/286459611.md)
*2026-05-14T12:02:00.000Z*
> Inhibrx Biosciences, Inc. reported its Q1 2026 financial results, showing a net loss of $33.4 million, an improvement fr

### [Top 10 US Stock Losers (5.12)](https://longbridge.com/en/news/286163538.md)
*2026-05-12T22:01:01.000Z*
> Power Solutions(PSIX) fell 39.15%, with a trading turnover 202.8 Million USD, and a year-to-date fell 33.5%. ZoomInfo Te

### [Inhibrx announces positive interim results from HexAgon trial](https://longbridge.com/en/news/286189050.md)
*2026-05-12T08:42:53.000Z*
> Inhibrx Biosciences announced positive interim results from its Phase II HexAgon trial for INBRX-106 in treating PD-L1 p

### [Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study](https://longbridge.com/en/news/286130658.md)
*2026-05-11T16:08:17.000Z*
> Inhibrx Biosciences (NASDAQ: INBX) announced interim Phase 2 results for INBRX-106 combined with Merck’s KEYTRUDA in tre